Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CLLS
CLLS logo

CLLS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cellectis SA (CLLS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.890
1 Day change
-0.51%
52 Week Range
5.480
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Cellectis SA (CLLS) is not a strong buy for a beginner investor with a long-term focus at this time. The stock shows no significant trading trends, lacks recent positive news or catalysts, and has no strong proprietary trading signals. While technical indicators are mixed, the lack of clear bullish momentum and the absence of strong financial or analyst support make this a hold rather than a buy.

Technical Analysis

The MACD histogram is slightly positive at 0.033 but contracting, suggesting weakening momentum. RSI at 46.58 is neutral, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below key pivot levels (Pivot: 4.073, Current Price: 3.91), showing resistance above the current price.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • Pre-market price drop of -4.02% and regular market decline of -1.76%. Lack of recent news or financial data to support growth. Stock trend analysis shows a likelihood of minor declines in the short term.

Financial Performance

No financial data available for analysis. Latest quarter financials could not be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available for evaluation.

Wall Street analysts forecast CLLS stock price to rise
4 Analyst Rating
Wall Street analysts forecast CLLS stock price to rise
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.910
sliders
Low
4
Averages
7
High
9
Current: 3.910
sliders
Low
4
Averages
7
High
9
Clear Street
Bill Maughan
initiated
$9
AI Analysis
2025-12-22
Reason
Clear Street
Bill Maughan
Price Target
$9
AI Analysis
2025-12-22
initiated
Reason
Clear Street analyst Bill Maughan initiated coverage of Cellectis with a Buy rating and $9 price target. Cellectis has produced "strong" efficacy data from its initial program, lasme-cel in acute lymphoblastic leukemia, and "an encouraging initial efficacy signal" from eti-cel in non-hodgkin's lymphoma, which the firm believes positions Cellectis well to be among the first companies to bring an allogenic CAR-T product for the treatment of hematological cancers to market.
Wells Fargo
Nick Abbott
Equal Weight
maintain
$3 -> $4
2025-10-20
Reason
Wells Fargo
Nick Abbott
Price Target
$3 -> $4
2025-10-20
maintain
Equal Weight
Reason
Wells Fargo analyst Nick Abbott raised the firm's price target on Cellectis to $4 from $3 and keeps an Equal Weight rating on the shares. The firm says new data from DL3 of ALL study are promising, with high CR/CRi & MRD-ve rates in patients with few options. Clarity on regulatory path is also positive, Wells adds. Pivotal Phase 2 execution is now key, with first data Q4 2026 and BLA filing in the second half of 2028, along with clarity on market size/opportunity.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CLLS
Unlock Now

People Also Watch